Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
DexCom (NASDAQ:DXCM) has launched its Time in Range Campaign in the UK, aimed at promoting awareness and adoption of the time-in-range metric in diabetes management. Despite the clinical benefits, a recent UK survey shows fewer than 50% of people with insulin-treated diabetes utilize this metric. Key findings reveal that 83% feel better when spending more time in range, yet 59% do not track it. Additionally, access to continuous glucose monitoring (CGM) technology varies significantly due to the UK's postcode lottery, affecting availability for many.
DexCom (NASDAQ:DXCM) will release its third quarter 2021 financial results after market close on October 28, 2021. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day, with a webcast available on the DexCom investor relations website. Investors can join the call by dialing (800) 446-1671 or (847) 413-3362 for international calls, using confirmation number '49591484'. DexCom is a leader in diabetes management, providing innovative continuous glucose monitoring systems.
Dexcom (NASDAQ: DXCM) announces that the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now eligible for provincial coverage in Manitoba for individuals with type 1 diabetes aged 25 and under. This move expands access to CGM technology, joining other provinces like British Columbia and Quebec that already provide coverage. The Dexcom G6 system allows users to monitor glucose levels continuously, reducing reliance on fingerstick tests. The initiative aims to improve diabetes management and health outcomes for young individuals with diabetes in Manitoba.
Dexcom (NASDAQ: DXCM) announces its G6 Continuous Glucose Monitoring (CGM) System is now covered by the Non-Insured Health Benefits (NIHB) Program for children and adolescents aged 2-19 requiring intensive insulin therapy. This coverage aims to improve access for First Nations and Inuit communities, potentially enhancing health outcomes for those living with diabetes. With proven benefits in glycemic control, the Dexcom G6 System provides real-time data and alerts, facilitating better diabetes management and support for families.
DexCom, Inc. (NASDAQ:DXCM) announced upcoming presentations at virtual investor conferences. Jereme Sylvain, CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 2:00 PM EST. Quentin Blackford, COO, will present at the Morgan Stanley 19th Annual Healthcare Conference on September 13, 2021, at 2:00 PM EST. Webcasts will be available on the DexCom Investor Relations site for live viewing and future reference.
DexCom reported second quarter 2021 financial results with revenue growth of 32% year-over-year, totaling $595.1 million. U.S. revenue increased by 26%, while international revenue saw a remarkable 58% growth. GAAP operating income reached $101.0 million (17% of revenue), up 200 basis points from the previous year. DexCom announced an increase in its 2021 revenue guidance to approximately $2.35 - 2.40 billion, reflecting strong momentum in the CGM market. The company also received FDA clearance for its real-time API.
DexCom has received FDA clearance for its real-time Partner Web APIs, enabling third-party developers to integrate continuous glucose monitoring (CGM) data into digital health apps and devices. This advancement aims to enhance user experience by providing more flexibility in viewing glucose data. Companies like Garmin and Teladoc Health's Livongo are involved in the integration process. The APIs will help users consolidate therapy data and receive personalized diabetes management coaching.
DexCom, Inc. (NASDAQ:DXCM) will release its Q2 2021 financial results on July 29, 2021, after the market closes. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the performance. Investors can access the call by dialing (800) 446-1671 for US/Canada or (847) 413-3362 for international calls, using the confirmation number 49591483. The call will also be webcast live, and the link will be available on the DexCom investor relations website.
DexCom, Inc. (NASDAQ: DXCM) recently highlighted key research at the 81st American Diabetes Association (ADA) virtual conference (June 25-29, 2021). The data emphasizes the critical role of continuous glucose monitoring (CGM) in diabetes management across various populations. Notably, presentations included analyses on CGM's effects on hypoglycemia control, glycemic control improvements, and healthcare cost reductions among Type 2 diabetes patients. Additionally, the conference showcased over a dozen studies linking CGM to enhanced health outcomes and quality of life.
DexCom (NASDAQ:DXCM) has launched The Global Movement for Time in Range, a campaign aimed at enhancing awareness and adoption of time in range metrics in diabetes management. Co-led by Nick Jonas, the initiative is backed by various diabetes organizations, aiming to inform patients about time in range's benefits and improve healthcare strategies. Survey data indicates that many insulin-treated diabetes patients lack awareness of this crucial metric, highlighting a significant opportunity for education and improved healthcare practices. The movement seeks to address these knowledge gaps.
